Amendments to the Claims

Listing of Claims:

1. (Original) A compound of the formula (I)



(I)

wherein

when K is 0, one of X_1, X_2, X_3, X_4, is a S or O atom and the others are independently selected from C, CH, or N; and wherein when j is 0, one of X_5, X_6, X_7, and X_8 is S, or O, and the others are independently selected from C, CH, or N; provided that both k and j are not simultaneously equal to zero or 1; and provided that each of rings A or B has no more than 2 nitrogen atoms;

n is 0, 1, 2, or 3;

k is 0 or 1; j is 0 or 1;

p is 0, 1 or 2;

E is O or NH;

R^1 and R^2 are independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, phenyl, C_1-C_{10} alkylaryl, $C(O)C_1$-C_8 alkyl, $CO(O)C_1$-C_8alkyl, SO_2C_1-C_8 alkyl, SO_2C_1-C_{10} alkylaryl, or SO_2C_1-C_8 alkylheterocyclic, C_4-C_{10} alkylcycloalkane, C_1-C_8 alkoxyalkyl, $(CH_2)_nC(O)OR^8$, $(CH_2)_nC(O)R^8$, $(CH_2)_mC(O)NR^8R^8$, and $(CH_2)_mNSO_2R^8$; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, phenyl, C_1-C_8 alkylaryl, $C(O)C_1$-C_8 alkyl, $CO(O)C_1$-C_8 alkyl, C_1-C_8 alkoxy, SO_2C_1-C_8 alkyl, SO_2C_1-C_8 alkylaryl, SO_2C_1-C_8 alkylheterocyclic, C_4-C_{10} alkylcycloalkane, $(CH_2)_nC(O)OR^8$, $(CH_2)_nC(O)R^8$; and wherein R^1 and R^2 may optionally combine with each other to form a 4, 5, 6, or 7-member nitrogen-containing heterocycle which nitrogen -containing heterocycle may have substituents

selected from the group consisting of oxo, amino, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, phenyl, C_1-C_8 alkylaryl, $C(O)C_1$-C_8 alkyl, $CO(O)C_1$-C_8 alkyl, halo, C_1-C_8 haloalkyl;

R^3 and $R^{3'}$ are each independently selected from Hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_1-C_8 alkoxy, C_1-C_8 thioalkyl, phenyl, aryl, C_1-C_8 alkylaryl;

R^4 and R^5 are each independently selected from Hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, C_1-C_8 alkoxy, halo, C_1-C_8 haloalkyl, phenyl, aryl, C_1-C_8 alkylaryl, $(CH_2)_mNSO_2C_1$-C_8 alkyl, $(CH_2)_mNSO_2$phenyl, $(CH_2)_mNSO_2$aryl, $-C(O)C_1$-C_8 alkyl, or $-C(O)OC_1$-C_8 alkyl; wherein each R^4 or R^5 is attached to its respective ring only at carbon atoms, and wherein y is 0, 1, 2, or 3; and wherein z is 0, 1, 2, or 3;

R^6 and R^7 are each independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, $C(O)C_1$-C_8 alkyl, hydroxy, C_1-C_8 alkoxy, SO_2C_1-C_8 alkyl, SO_2C_1-C_8 alkylaryl, or SO_2C_1-C_8 alkylheterocyclic, aryl, C_1-C_8 alkylaryl, C_3-C_7 cycloalkane, C_1-C_{10} alkylcycloalkane, $(CH_2)_nC(O)OR^8$, $(CH_2)_nC(O)R^8$, $(CH_2)_mC(O)NR^8R^8$, and $(CH_2)_mNSO_2R^8$; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, phenyl, and C_1-C_8 alkylaryl; and wherein R^6 and R^7 may independently combine together, and with the nitrogen atom to which they are attached or with 0, 1, or 2 atoms adjacent to the nitrogen atom to which they are attached to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may further have substituents selected from the group consisting of oxo, amino, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, phenyl, C_1-C_8 alkylaryl, $C(O)C_1$-C_8 alkyl, $CO(O)C_1$-C_8 alkyl, hydroxy, C_1-C_8 alkoxy, halo, and haloalkyl;

R^8 is hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_5-C_8 alkylaryl, $-C(O)C_1$-C_8 alkyl, or $-C(O)OC_1$-C_8 alkyl; m is 1, 2, or 3; or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomers or mixtures thereof.

2. (Original) The compound according to claim 1 wherein the A-ring is selected from the group consisting of phenyl, pyridyl, thiophene, thiazole, furanyl, imidazole, and pyrazole.

3. (Cancelled)

4. (Original) A compound according to Claim 1 wherein the B-ring is selected from the group consisting of phenyl, thiophene, thiazole, furan, and pyridine.

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Original) A compound according to Claim 1 wherein y is 0, or 1, and R^4 is independently selected from the group consisting of hydrogen, fluoro, chloro, methyl, methoxy, ethoxy, ethyl, isopropyl, trifluoromethyl, phenyl, and benzyl.

13. (Original) A compound according to Claim 1 wherein z is 0, or 1, and R^5 is independently selected from the group consisting of hydrogen, fluoro, chloro, methyl, methoxy, ethoxy, ethyl, isopropyl, trifluoromethyl, phenyl, and benzyl.

14. (Original) A compound according to Claim 1 wherein R^1 and R^2 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, phenyl,



15. (Original) The compound according to Claim 1 wherein R^6 and R^7 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, and phenyl.

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Original) A compound selected from the group consisting of:
5-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-thiophene-2-carboxamide,
5-{4-[(3,3-Dimethyl-butylamino)-methyl]-phenoxy}-thiophene-2-carboxamide,
5-{4-[(2-Cyclopentyl-ethylamino)-methyl]-phenoxy}-thiophene-2-carboxamide,
5-{4-[(3-Ethyl-pentylamino)-methyl]-phenoxy}-thiophene-2-carboxamide,
5-{4-[(Cyclohexylmethyl-amino)-methyl]-phenoxy}-thiophene-2-carboxamide,
5-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-thiophene-2-carboxamide,
5-{2-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-thiophene-2-carboxamide,
5-{2-Chloro-4-[(3,3-dimethyl-butylamino)-methyl]-phenoxy}-thiophene-2-carboxamide,
5-(2-Chloro-4-{[2-(4-fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-thiophene-2-carboxamide,
5-{2-Fluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-thiophene-2-carboxamide,
5-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-phenoxy}-thiophene-2-carboxamide,
5-(2-Fluoro-4-{[2-(4-fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-thiophene-2-carboxamide,
5-{2-Methoxy-4-[(3-methyl-butylamino)-methyl]-phenoxy}-thiophene-2-carboxamide,
5-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)-thiophene-2-carboxamide,
4-{5-[(3-Methyl-butylamino)-methyl]-thiazol-2-yloxy}-benzamide,
3-Methoxy-4-{5-[(3-methyl-butylamino)-methyl]-thiazol-2-yloxy}-benzamide,

4-{5-[(3,3-Dimethyl-butylamino)-methyl]-thiazol-2-yloxy}-benzamide,
4-(5-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-thiazol-2-yloxy)-benzamide,
4-(5-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-thiazol-2-yloxy)-3-methoxy-benzamide,
4-{5-[(Cyclohexylmethyl-amino)-methyl]-thiazol-2-yloxy}-benzamide,
2-(4-Pentylaminomethyl-phenoxy)-thiazole-5-carboxamide,
2-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-thiazole-5-carboxamide,
2-{4-[(3,3-Dimethyl-butylamino)-methyl]-phenoxy}-thiazole-5-carboxamide,
2-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-phenoxy)-thiazole-5-carboxamide,
2-{2-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-thiazole-5-carboxamide,
2-{2-Fluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-thiazole-5-carboxamide,
2-{2-Methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-thiazole-5-carboxamide,
2-{2-Methoxy-4-[(3-methyl-butylamino)-methyl]-phenoxy}-thiazole-5-carboxamide,
4-[5-(2,6-Dimethyl-morpholin-4-ylmethyl)-thiazol-2-yloxy]-benzamide,
4-{5-[(3-Methoxy-propylamino)-methyl]-thiazol-2-yloxy}-benzamide,
4-{4-Chloro-5-[(3-methyl-butylamino)-methyl]-thiazol-2-yloxy}-benzamide,
4-(5-Butylaminomethyl-4-chloro-thiazol-2-yloxy)-benzamide,
4-{4-Chloro-5-[(3,3-dimethyl-butylamino)-methyl]-thiazol-2-yloxy}-benzamide,
4-[5-(Phenethylamino-methyl)-thiophen-2-yloxy]-benzamide,
4-{5-[(3-Methyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide,
4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-thiophen-2-yloxy)-benzamide,
4-{5-[(2-Cyclopentyl-ethylamino)-methyl]-thiophen-2-yloxy}-benzamide,
4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-thiophen-2-yloxy}-benzamide,
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide,
3-Methoxy-4-[5-(phenethylamino-methyl)-thiophen-2-yloxy]-benzamide hydrochloride,
3-Methoxy-4-{5-[(3-methyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide hydrochloride,
4-[5-(2-Phenethylamino-ethyl)-thiophen-2-yloxy]-benzamide hydrochloride,
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomric mixture thereof.

21. (Original) A compound selected from the group consisting of:

4-[5-(Phenethylamino-methyl)-thiophen-2-yloxy]-benzamide



4-{5-[(3-Methyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide



4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-thiophen-2-yloxy)-benzamide



4-{5-[(2-Cyclopentyl-ethylamino)-methyl]-thiophen-2-yloxy}-benzamide



4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-thiophen-2-yloxy}-benzamide



4-{5-[(3,3-Dimethyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide



3-Methoxy-4-[5-(phenethylamino-methyl)-thiophen-2-yloxy]-benzamide hydrochloride



3-Methoxy-4-{5-[(3-methyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide hydrochloride



4-[5-(2-Phenethylamino-ethyl)-thiophen-2-yloxy]-benzamide hydrochloride



5-{4-[(3-Ethylpentylamino)methyl]phenoxy}thiophene-2-carboxamide



2-{4-[(3-Methylbutylamino)methyl]phenoxy}thiazole-5-carboxamide



2-(4-{[2-(Tetrahydropyran-4-yl)ethylamino] methyl}phenoxy)thiazole-5-carboxamide methanesulfonate



and a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomeric mixture thereof.

22. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I in association with a carrier, diluent and/or excipient.

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Currently Amended) A method ~~according to Claim 25 wherein the~~of treating or preventing obesity and Related Diseases ~~is selected~~selected from the group consisting of diabetes, diabetic complications, diabetic retinopathy, atherosclerosis, hyperlipidemia, hypertriglycemia, hyperglycemia, and hyperlipoproteinemia, irritable bowel syndrome, depression, smoking and alcohol addiction, sexual dysfunction, substance abuse, drug overdose, addictive behavior disorders, compulsive behaviors, and stroke comprising administering a therapeutically effective amount of a compound of formula I.

27. (Original) A method of suppressing appetite comprising administering a therapeutically effective amount of a compound of formula I to a patient in need thereof.

28. (Cancelled)